Should You Buy AbbVie in April?

AbbVie (NYSE: ABBV) is one of those stocks that should be in everyone's portfolio. It's rare to find its mix of growth and value (plus a really good dividend). The pharmaceutical company has enjoyed a run of six consecutive years of double-digit earnings per share (EPS) growth, and management says they expect more of the same this year. Last year, the company posted EPS of $10.52 per share, a rise of more than 18% year over year. AbbVie expects adjusted diluted EPS for full-year 2021 of $12.32 to $12.52. It posted $45.8 billion in revenue last year, an increase of 37.7% year over year on a reported basis.

The company's share price rose 22% over the last year and has been flat over the past month. Is now the time to buy in? 

Continue reading

Source Fool.com